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Abstract 
Five organic salts of the antiplasmodial drug piperaquine (PQ, C29H32Cl2N6) were synthesized and 
characterized by X–ray diffraction methods. The corresponding solubilities in water and acetic acid 
solutions were evaluated in the 20 – 50 ºC (293 – 323 K) T range by UV–Vis spectroscopy, with the 
aim of elucidating how they depend on chemical, structural and thermodynamic factors. Experiments 
were complemented by DFT calculations, both in vacuo and in the solid state, to estimate changes in 
thermodynamic state functions related to the solvation process. It is demonstrated that solubility is 
mainly governed by electronic and chemical properties of the anion, while lattice energies and 
packing effects, including in–crystal conformational changes of the drug, play a less important role. 
PQ salts generally conform to the predictions of Hard and Soft Acid and Bases (HSAB) theory, as 
less soluble compounds bear ions of comparable hardness, and vice–versa. A remarkable exception, 
is the PQ hydrogen sulfate salt, whose poor solubility can be ascribed to an exceptionally stable 
crystal lattice. Other factors, such as entropic effects related to solid–state disorder, can influence the 
response of solubility to temperature.  
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1. Introduction 
Piperaquine1 (PQ, scheme 1) is a 4–aminoquinoline (4–AQ) antiplasmodial bearing two substituted 
7–chloroquinoline moieties, connected by a double piperazinyl bridge.  
 
Scheme 1 
To date, few investigations deal with the clinical pharmacokinetics of the sole PQ,1–4 and no 
direct evidences even exist on its mechanism of action at the molecular level. The simpler and cheaper 
4–AQ compound chloroquine5,6 is often considered as a prototypical model for the action of  drugs 
of this class. Thus, it is far more studied by both experimental7–9 and computational7,10,11 techniques, 
even though it is nowadays nearly ineffective due to specific resistance evolved by Plasmodium 
falciparum, the most aggressive and dangerous malaria parasite. On the contrary, in combination with 
artemisinin derivatives,12 PQ is still employed worldwide in antimalarial multi–drug treatments.1,13,14 
Yet, parasites able to survive such therapies appeared in the last decade in Southeast Asia,15,16 raising 
the urgent problem of continuously developing new strategies to win the race against the Plasmodium 
adaptability. 
It is widely accepted that 4–AQ antimalarials interfere with the heme detoxification process 
in the acidic (pH ≅ 5) digestive vacuole (DV) of Plasmodium protozoa.17 It is believed that their target 
is the heme molecule, either in the form of Fe(III)protoporphyrin in solution,5–7 or at the surface of 
growing hemozoin crystals.18 The structure of the heme–drug adduct, however, is still debated. 
Relevant actors in the recognition process should be (i) π···π stacking interactions between the 
quinoline core of the drug and the heme pyrrolic subunits,8,9 perhaps associated to (ii) a direct 
coordinative Fe–N bond involving quinoline nitrogen atoms.6,19 Also (iii) charge–assisted hydrogen 
bonds (CAHBs) involving the aliphatic amines of the 4–AQ system as donors might play a role.5 
When PQ comes into play, the problem is complicated by the large conformational freedom 
of the hydrocarbon bridge connecting the two aminoquinoline moieties (Scheme 1), which in 
principle could allow different interaction modes with respect to less flexible drugs of the same class. 
Moreover, the title compound bears four basic amine functions, with pKa = 6.88, 6.24 (tertiary N) 
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and 5.72, 5.39 (quinoline N).20 Thus, in the acidic DV, the main forms in equilibrium are H3PQ3+ and 
H4PQ4+, with a slight preference for the fully protonated one (Figure S1 SI).  
Beyond the mechanism of action of a medical drug, it is well known how its solubility and 
dissolution rate as well as other physical (appearance, density and hygroscopicity, thermodynamic 
stability) and chemical (integrity and labelled potency) properties can change dramatically with the 
solid form (salts, polymorphs, solvates, co-crystals, amorphous forms). It follows that, the chemical 
form and the solid phase of a pharmaceutical ingredient can have a great impact on the bioavailability 
and the overall stability of the drug but also on the convenience in production and storage of the final 
product. Since most of the drug molecules, like PQ, are either weak acids or bases, that is, possess 
ionic sites in their molecule, salt formation represents a useful and simple chemical way to modify 
the properties of the drug substances.21 However, in a salt screening study the choice of a salt, and 
the salt formation feasibility, is largely ruled by acid-base chemical aspects, toxicological 
implications, dosage form considerations, pharmacological indications and marketing 
preferences.22,23  Many organic counterions and some of the common inorganic ions (i.e. calcium, 
phosphate, chloride) show a very good tolerability and a low toxicity because are components of food, 
natural constituents of the body or involved in the metabolic cycles. For many other anion species, 
specific remarks must be addressed.  
It must be made clear that, according to medicinal evaluation authorities, different salt forms 
are not bioequivalent or exchangeable. In fact, albeit rare, counterions can lend an additional 
therapeutic action to the active ingredient or modify the toxicity of the parent compound, influence 
the formulation characteristics, change the release properties and the delivery mechanism. 
At present, the number of acceptable salt formers, deemed as harmless components, is quite 
reduced and the choice is essentially limited to a list of counteranions categorized in three classes 
based on a toxicity criteria23,24 (Class 1: no restrictions to use, physiological and metabolic ubiquitous 
ions; Class 2: limited use, not natural ions, low toxicity; Class 3: occasionally use, not natural ions, 
secondary effects). A regulatory guidance for the acceptance of new salt forms of already approved 
active ingredients is still yet available. 
 The neutral form of lipophilic PQ,3 (Section S2.1 SI) is not soluble in water as well as the salt 
from (hydrogen phosphate tetrahydrate) mainly used in the commercial formulations25 that results in 
a reduced oral bioavailability of the drug.2 Investigating which factors govern the solubility of PQ is 
therefore interesting in the context of developing new and more advantageous formulations. To date, 
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however, systematic studies on the possibility of enhancing the solubility of piperaquine salts are 
lacking. 
In the present work, our goal is to understand how chemical and crystallographic factors are 
intertwined in determining the solubility of PQ salts. At the same time, we investigate how different 
non–covalent interaction (NCI) networks govern molecular conformation and packing in the solid 
state. To synthesize new PQ–based compounds, to be compared with the phosphate tetrahydrate one, 
four acid system are considered as salt-former, that is,  sulfate (ordinary, class 1), bromide and nitrate 
(less common, class 2) and triflate (uncommon). Though the therapeutic use of their salts cannot be 
excluded a priori, nitrate and triflate  have been chosen only on a chemical basis to span as widely as 
possible the landscape of structure–properties relationships. This is because nitrate anion has always 
been considered as both a toxic constituent of the diet, strictly regulated in water and food, and an 
inert specie endogenously generated from nitrogen monoxide (NO).26 However, due to its recognised 
adverse physiological effects, nitrate ion is generally not recommendable, although not prohibited, 
for salt conversion of drugs.27 For the triflate base, no biological or physiological data are available. 
An in-silico approach to define potential toxicity problems and assess the safety of triflate and other 
potential inorganic and organic ionic components in pharmaceutical medicaments could be 
performed, even though a clear general predictive model in computational toxicology is not yet 
available.28,29  
 
2. Methods 
2.1 Synthesis. Reagent–grade chemicals (≥ 98% purity) were purchased from Sigma Aldrich 
and used without further purification. 1,3–bis[4–(7–chloroquinolin–4–yl)piperazin–1–yl]propane 
(piperaquine) tetraphosphate tetrahydrate (PPT) salt was directly employed for UV–vis 
measurements (see below). All the other compounds were obtained according to the following 
procedures. 
2.1.1 Neutral PQ. ~ 1 g of commercial PPT was dissolved in 40 mL of aqueous acetic acid 10 
M. Concentrated aqueous NH3 was added dropwise under continuous stirring up to pH = 8. The 
precipitation of neutral PQ started at pH = 6. The powder was filtered, washed with deionized water 
and dried in oven at 40°C. The structure was confirmed by powder X-ray diffraction (XRPD) and 
was identical to that recently reported by Wang et al..30 X–ray quality single crystals were grown 
from CHCl3 by slow evaporation at room temperature.  
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2.1.2 PQ tetraphosphate tetrahydrate ((H4PQ4+)(H2PO4–)4·4H2O, PPT). X–ray quality single 
crystals were obtained upon recrystallization of commercial PPT (0.2778 g) from 1 M aqueous acetic 
acid (20 mL). The solution was placed in a Petri dish (∅ 50 mm) and left free to evaporate overnight 
at room temperature (RT).  
2.1.3 PQ hydrogen sulfate hydrate ((H4PQ4+)(HSO4–)5·nH2O·H3O+, PHS). 0.3075 g of 
commercial PPT were put into 70 mL of aqueous 1 M H2SO4 in a glass flask. 5 mL of concentrated 
H2SO4 were added and the suspension heated under continuous stirring at 55ºC (328 K) until complete 
dissolution. After cooling down to room temperature, the solution was poured in a Petri dish (∅ 100 
mm) and left free to evaporate overnight. Eventually, plate–like red PHS crystals suitable for the 
single crystal X–ray analysis were obtained. An equivalent synthetic route consists in dissolving 
0.4306 g of neutral piperaquine (§ 2.1.1) into 105 mL of aqueous H2SO4 10 M and leaving the solution 
free to evaporate in a Petri dish (∅ 60 mm) at room temperature. After ~ 2 months, plate–like crystals 
of PHS were filtered, dried and ground in a mortar. The identity of the material was confirmed by 
XRPD ; UV–vis measurements were performed on the ground powder (see below).  
2.1.4. PQ triflate trihydrate ((H4PQ4+)(CF3SO3–)4·3(H2O), PTT). 0.4312 g of neutral PQ (§ 
2.1.1) were put into 16 mL of aqueous trifluoromethanesulfonic acid (CF3SO3H) 4.2 M. Complete 
dissolution was obtained only by adding 34 mL of supplementary acetic acid 10 M. Then, the solution 
was poured in a Petri dish (∅ 60 mm) and left free to evaporate in air at room temperature. After ~ 1 
week, several small crystals appeared; in ~ 2 weeks, well–formed, transparent and colorless prisms 
were present. Some specimens were selected for single–crystal X–ray diffraction, and the remaining 
material ground in a mortar to perform solubility measurements (see below).  
2.1.5. PQ bromide trihydrate ((H4PQ4+)(Br–)5·3H2O·H3O+, PBT). 0.0508 g of neutral PQ (§ 
2.1.1) were added to 8 mL of HBr in acetic acid (32%) and 3 mL of distilled water. The suspension 
was stirred until complete dissolution, poured into a 25 mL glass flask and left free to evaporate in 
air at room temperature. Upon resting, the solution became immediately cloudy; very small crystals 
quickly formed on the internal glass surfaces of the flask. The precipitate was filtered, added to 5 mL 
of CH3COOH 10 M and stirred until complete re–dissolution. After ∼ 1 month, prismatic crystals 
formed by slow evaporation at room temperature. One of them was selected for the X–ray analysis, 
and the remaining material ground into a powder for the UV–vis measurements. 
2.1.6. PQ nitrate ((H4PQ4+)(NO3–)4·(HNO3)3, PN). 0.4707 g of neutral PQ (§ 2.1.1) were 
added to 30 mL of aqueous HNO3 9.5 M. Complete dissolution was achieved only after the addition 
of 65% nitric acid up to a final volume of 65 mL. The solution was left free to evaporate at room 
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temperature in a Petri dish (∅ 80 mm). After 6 days, only one large crystal of PN had appeared. 
Smaller crystals formed in subsequent days, but tended to dissolve spontaneously. When the first 
specimen was almost 1 cm long, a couple of smaller crystals began to steadily grow. One of the latter 
was selected to undergo X–ray diffraction. The rest of the material was ground in a mortar to be 
investigated by means of XPRD and UV–vis techniques (see below). 
 
Table 1. Crystallographic and refinement details of hydrogen phosphate (PPT), hydrogen sulfate 
(PHS), triflate (PTT), bromide (PBT) and nitrate (PN) salts of fully protonated piperaquine (H4PQ4+).  
 
Substance PPT PHS PTT PBT PN 
Temperature / K 150(2) 120(2) 298(2) 120(2) 296(2) 
Crystal data      
Formula 
(H4PQ4+) 
(H2PO4–)4  4·H2O 
(H4PQ4+)(HSO4–)5  
6.6·H2O H3O+ 
(H4PQ4+)  
(CF3SO3–)4 3·H2O 
(H4PQ4+)(Br–)5  
3·H2O H3O+, 
(H4PQ4+) 
(NO3–)4 (HNO3)3 
Z, Z’ a 4, 1 4, 1 8, 1 1, 0.5 2, 1 
Space group P21/n Cc C2/c P–1 P–1 
a / Å 22.276(1) 21.4922(7) 19.031(4) 7.4928(2) 11.250(6) 
b / Å 7.4516(4) 7.3576(2) 18.208(4) 14.3820(4) 13.6923(8) 
c / Å 27.897(1) 29.6485(10) 16.149(3) 17.6634(4) 14.6995(9) 
α / deg 90. 90. 90. 88.936(1) 68.320(1) 
β / deg 107.385(1) 101.563(2) 118.92(3) 80.414(1) 84.958(1) 
γ / deg 90. 90. 90. 84.701(1) 83.067(1) 
V /Å3 4419.2(4) 4591.7(2) 4898(2) 1853.11(8) 2081.8(2) 
Density  / g·cm–3 1.490 1.662 1.604 1.814 1.558 
µ / mm–1 0.373 0.469 0.417 5.608 0.255 
      
Data collection      
Measured reflns 55499 31452 42406 27494 31574 
Unique reflns. 10187 10564 5631 8522 11874 
Obs. (I>2σ(I)) unique reflns 7792 10194 4580 7721 9244 
Completeness / % 100.0  100.0 100.0  99.9 99.3 
Rint 0.033 0.015 0.024 0.019 0.019 
      
Refinement      
Max resolution / Å 0.769 0.769 0.769 0.769 0.714 
R(F), I > 2 σ(I) 0.058 0.042 0.059 0.020 0.046 
wR(F2), all 0.178 0.122 0.187 0.048 0.136 
Goodness–of–fit 1.044 1.044 1.047 1.007 1.037 
∆ρMAX, ∆ρMIN / e·Å–3 1.220, –0.654b 0.608, –1.000
 b 0.557, –0.611  0.573, –0.684  0.394, –0.477  
a Z: Number of chemical formulae of piperaquine in the unit cell; Z’: Z/mult, where mult is the crystallographic multiplicity 
of the general position. 
b Large Fourier residuals in the PPT and PHS structures are due to highly disordered chemical species. See Sections S2.3 
and S2.4 in the Supplementary Information for a full discussion of disorder. 
 
2.2 Single–crystal X–ray diffraction (SCXD). SCXD experiments were carried out on a 
Bruker Smart three–circle diffractometer equipped with an Apex II CCD detector and an Oxford 
Cryosystem 600 nitrogen blower. Graphite–monochromated Mo Kα radiation (λ = 0.71073 Å) at a 
nominal power of 50 kV x 30 mA was used in conjunction with a ω–scan collection strategy at 
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variable time intervals (20–40 s/frame) and steps of 0.5 deg. All the experiments were performed in 
controlled temperature conditions between 100(2) K and 296(2) K, with maximum resolution in the 
0.71–0.77 Å–1 interval of sinθ/λ and completeness ranging from 99.3 % to 100.0 % (Table 1). 
SAINT+31 and SADABS32 programs were employed, respectively, for data reductions and either 
empirical (PQ, PPT, PHS, and PN) or analytical (PTT and PB) absorption corrections. The structures 
were solved by direct methods and refined within the spherical atom approximation with the least–
square procedure implemented in the Shelx suite of codes.33 Geometries of hydrogen atoms were 
idealized, and riding–motion restraints (HFIX n3) applied throughout. All the X–H bond distances 
(X = C, N, O) were renormalized a posteriori to neutron–derived estimates34 by Mercury v3.9.35 
Table 1 below summarizes relevant crystallographic details, while Section S2 SI provide full 
information on the main features of the crystal packing of the various structures.  
2.3 Solubility measurements. The solubility of the PQ salts was measured at intervals of 5°C 
in the 20°C – 50°C range of T by means of UV-vis spectroscopy. A procedure similar to that detailed 
by Daneshfar et al.36 was adopted throughout. Each powdered compound was put in a small glass 
flask with a minimum amount of reagent–grade water and kept at the desired temperature for 2 hours 
under continuous stirring. A Huber circulation thermostat CC-205B was employed, exploiting a 
precision of ± 0.1 K. Then, stirring was stopped and the suspension left free to rest at constant 
temperature for 30 minutes. Samples of 20 µL (10 µL for PN) were harvested from the liquid near 
the surface and diluted in 10 mL of either reagent–grade water or acetic acid 1 M within a volumetric 
flask. The acetic acid guarantees the quantitative solubilization of the drug and thus tests in acidic 
solutions are useful benchmark against the actual solubility in water. The UV–vis absorbance of these 
solutions was measured immediately at 349 nm in H2O and at 344 nm in acetic acid. 
Absorbance measurements were performed in the 200–800 nm range at a scan rate of 1 nm/s 
with a Beckman Coulter DU–800 spectrophotometer equipped with D2 and tungsten sources. The 
maximum error on the measured absorbance should be lower than 0.005. Quartz cuvettes with optical 
length of 1 cm were used throughout.  
2.4 Quantum simulations. Single–point periodic DFT calculations were carried out starting 
from the experimental structures of the synthesized compounds (Section 2.2) with the CRYSTAL14 
program37 to retrieve information on the lattice energies. The Minnesota–class meta–GGA M06 
functional38 was used in conjunction with basis sets taken from the CRYSTAL library39–44 and 
optimized for solid–state calculations. Truncation criteria of the Coulomb and exchange series were 
set either to 10–8 or 10–16 (TOLINTEG 8 8 8 8 16). A level shifter of 0.3 h and a 80 % mixing of the 
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Kohn–Sham matrix coefficients were applied to subsequent SCF cycles to accelerate convergence.37 
A 4 x 4 x 4 sampling of the independent part of the first Brillouin zone defined the k–space grid where 
the SCF problem is iteratively solved. In disordered structures (Section S2 SI), preliminary partial 
geometry optimizations were carried out to determine the uncertain positions of hydrogen atoms, 
typically belonging to co–crystallized solvent. Only disordered sites with the highest occupation 
factors were modelled. More details are given in Section S3 SI. 
Crystal cohesive energies, Ecoh, are defined as:45–49   
( )∑
=
∆−∆+−=
n
i
iii EEEEE
1
BSSE,rel,iso,bulkcoh     (1) 
The summation runs over the n molecules in the unit cell, whose total electronic energy is 
Ebulk; Eiso,i is the energy of the i–th molecule extracted from the crystal (keyword37 MOLECULE), 
frozen at its solid–state conformation. The negative ∆Erel,i term accounts for the relaxation energy, 
i.e. for the energy difference between a molecule fully relaxed in vacuo and the same molecule at its 
solid–state geometry. Eventually, ∆EBSSE,i is the positive correction for basis set superposition error 
of the i–th molecule according to the counterpoise method by Boys & Bernardi,50 here applied within 
a maximum cutoff distance of 6.5 Å. 
Isolated molecules were also simulated with the Gaussian09 program.51 The same basis set 
used in solid–state calculations was exploited in conjunction with a DFT B3LYP hamiltonian, 
exploiting experimental solid–state geometries as references. In vacuo calculations provide (i) 
relaxation terms, ∆Erel, to crystal cohesive energies; (ii) reasonable estimates of chemical hardness of 
the anions, η, which can be computed as η = ½ (εHOMO–εLUMO) once the energies of the frontier 
orbitals, εHOMO and εLUMO, are known, under the assumption that the Koopmans’ theorem holds true; 
(iii) hydration energies of individual molecular ions (see Section 4). To this end, the solvent was 
implicitly simulated within the Polarizable Continuum Model (PCM) formalism, exploiting the 
Solvation Model based on Density (SMD) variation of Truhlar,52 which is recommended when 
dealing with solvation thermodynamics.51 Finally, simulations on isolated H4PQ4+ molecular pairs 
frozen at their experimentally–derived geometries were carried out to estimate the stabilizing 
contributions due to π⋅⋅⋅π stacking interactions, according to the procedure detailed in Section S4 SI.  
2.5 Quality assessment and reproducibility. Processing of diffraction data and quantum 
simulations were performed using commercial programs. Full details on the refinement procedure are 
deposited in the Supporting Information (Section S2 SI). CCDC 1882786-1882791 contain the 
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supplementary crystallographic data for this paper. These data can be obtained free of charge from 
The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures.  
  
3. Results  
3.1 Comparison of the H4PQ
4+ salt structures. Detailed descriptions of the packing modes of 
the synthesized salts (PPT, PHS, PTT, PBT and PN) are deposited in the SI (Section S2). Figure 1 
shows the Hirshfeld surface fingerprint plots53 of the various H4PQ4+ ions in different crystalline 
environments, as computed by the CrystalExplorer54 suite of programs. They share a general 
similarity in the overall shape, indicating that most key crystal packing features are recurrent, but 
differ in finer details, reflecting specific peculiarities of the different NCI networks. The similarities 
among different PQ salts are particularly relevant in this context: we expect that conserved NCI are 
most likely due to true structure–determining factors. 
 
Figure 1. Hirshfeld surface fingerprint plots of PPT (hydrogen phosphate), PHS (hydrogen sulfate), 
PTT (triflate), PBT (bromide) and PN (nitrate) salts of piperaquine. 
 
First, all the fingerprint plots are markedly asymmetric, indicating that H4PQ4+ does not 
preferentially set up close contacts with symmetry images of itself. Rather, PQ cations tend to be 
surrounded by anions, as expected in organic salts. With the only exception of the bromide compound 
(PBT), a very long and broad spike is always apparent in the lower left part of the diagram, 
representative of strong NH+···O– CAHBs at very short (di + de ≈ 1.6–1.8 Å) H···O contact distances. 
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In general, all the 4 N–H functions in protonated piperaquine are generally involved in close contacts 
with anions; only in the PTT salt, the aliphatic NH+ groups are connected with two neutral water 
molecules, while triflate anions prefer to approach quinoline NH+ donors. This is likely due to the 
higher dimensions of CF3SO3– ions, which result in a reduced accessibility of the cation in the more 
sterically crowded regions of the aliphatic nitrogen atoms, while the piperaquine molecule exploits 
here a less extended conformation (see Section 3.2 below). Accordingly, H4PQ4+ in PTT sets up only 
two CAHB interactions per molecule, to be compared with the four CAHBs formed in the other salts 
here considered.  
Second, a pronounced spike is also evident in PHS at short di ≈ de ≈ 0.8–0.9 Å along the main 
diagonal. A similar feature, though less marked and shifted at longer di + de, is also present in the 
nitrate PN salt. They are both the signature of ubiquitous close H···H contacts, which in PHS include 
very short ones ( < 2 Å) that arise due to the closeness of co–crystallized water molecules. 
Third, all the fingerprint plots also share a similar spike at di + de ≈ 2.7 Å, in the lower right 
part of the plane. This originates from CH(piperazine ring)···Cl contacts in which PQ plays the role 
of the acceptor. In fact, it is mirrored by an analogue feature in the upper left part of the diagram, in 
most cases partly covered by the CAHBs signature, which accounts for the same interaction from the 
donor’s viewpoint. Another interesting region is the one located at di ≈ de ≈ 1.8 Å along the main 
diagonal, which it always bear a significant contact frequency and signals the occurring π···π contacts 
among flat rings. Some differences emerge as well, though. Such interactions are more frequent in 
the sulfate salt (PHS), where “sandwich–like” arrangements among neighboring quinoline rings are 
the preferred stacking mode (Section S2.4 SI). This is in agreement with geometrical and energetic 
parameters computed for these stacking interactions (Table S7 SI).  
In the bromide structure (PBT), the signature of stacking interactions is barely apparent in the 
fingerprint plot (Figure 1) and, accordingly, it does not provide significant contributions to the lattice 
stabilization (Tables S7 and S8 SI). On the contrary, a bright veining runs along the main diagonal of 
the diagram, marking Cl⋅⋅⋅Br contacts with bromide ions. Other differences concern the hydrogen 
bond pattern. According to Shannon,55 the effective ionic radius of Br– is 1.96 Å, i.e. it has larger 
dimensions than an oxygen acceptor, but at the same time it is significantly smaller than any other 
molecular anion considered in this work. Thus, H+···Br– contacts are longer than the H+···O– ones, 
and appear in the fingerprint plot as a sharp and brilliant spike at minimum di+de ≈ 2.2 Å in the upper 
left region of the diagram. A secondary, parallel spike also appears at a similar di+de, but shorter than 
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the first one and translated toward greater di’s, which is due to weaker CH···O contacts involving 
water oxygen atoms.  
  
3.2 In–crystal conformation of PQ. The packing differences described in Section 3.1 are 
intertwined with the conformational freedom of the PQ molecule. Indeed, the title compound can 
easily undergo conformational changes to fit specific packing requirements, according to the chemical 
nature and arrangement of anions and water in the lattice. Figure 2 sketches the main rotatable bonds 
and groups in PQ. The puckering state of the piperazinyl substituents has no effect, as the only 
detected conformer is the chair–like one (see Section S5 SI).  
 
 
Figure 2. (a) Main torsional conformational descriptors of PQ. αPA and βQA are the angles between 
the piperazine (pink) and the quinoline (yellow) mean planes. (b–f) Structures of PQ molecular ions 
as found by X–ray crystallography in the phosphate (b), hydrogen sulfate(c), triflate (d), bromide (e) 
and nitrate (f) salts. Hydrogen atoms are omitted for clarity. Atom labels are indicated.  
 
The τ1, τ2 and τ3 torsion angles (Figure 2, Table 2) determine the general conformation of the 
H4PQ4+ ions and, in particular, the overall molecular symmetry. In PTT, half of a PQ molecule is 
symmetry–dependent on the other half through a C2 axis passing through the C16 methylene group 
in the mid of the hydrocarbon –(CH2)3– linker (Section S2.5 SI). Thus, τ1a, τ2a and τ3a are identical to 
the corresponding descriptors, τ1b, τ2b and τ3b, of the symmetry–related fragment. Increasingly larger 
differences between these two sets of torsions imply significant asymmetries. Interestingly, three out 
of five crystal structures bear H4PQ4+ moieties in fully symmetric (PTT) or almost symmetric (PPT 
and PHS) arrangements (Table 2). In PHS, despite the absence of any symmetry element within the 
molecule, the two sets of torsions remain identical; in PPT, the only significant difference concerns 
a ≈ +15° opening of τ2b with respect to τ2a. In the PBT and PN structures, on the contrary, the two 
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sets of dihedrals are no longer similar, with τ2b wider than τ2a by more than 100°, and τ3b ≈ –τ3a. 
Different settings of the τ angles often imply a change in the mutual orientation of the quinoline rings, 
as it can be appreciated by looking at the terminal C–Cl bonds in Figure 2. Being τQ the angle between 
the quinoline moieties, defined through the atom sequence C4A–C4–C24–C24A (Figure 2), τQ > 90º 
or τQ < –90º indicate an “anti” conformer (PPT, PHS and PBT), whereas –90º < τQ < +90º implies a 
“syn” one (PTT and PN). The dihedral angle βQA between the mean least–squares planes of the 
quinoline C–N backbones provides further insights. Values of βQA close to zero imply that the two 
quinoline rings are almost parallel to each other; if also the absolute |τQ| dihedral is small, they lie 
almost exactly on the same plane. This is the case of the nitrate structure, PN, where the PQ ions are 
essentially “flat” due to symmetry constraints. On the contrary, in PBT and PTT, large |τQ| and small 
βQA imply that the two aromatic systems are parallel, but do not lie on the same plane, setting up a 
sort of “ladder” conformation. In PHS and PPT, eventually, quinoline groups are tilted  (βQA > 20°), 
determining the preference for a “vane mill” conformation. Interestingly, the latter conformer is 
invariably associated to the energetically most favorable stacking arrangements in PPT and PHS 
(Section S4 SI).  
 
Table 2. Conformational descriptors of piperaquine cations in hydrogen phosphate (PPT), hydrogen 
sulfate (PHS), triflate (PTT), bromide (PBT) and nitrate (PN) salts. Estimated standard deviations are 
given in parentheses. 
 
Structure τ1a/τ1b a τ2a/τ2b a τ3a/τ3b a τQ b βQA c dNN
 d αPA e 
PPT –10.9(4)/–12.7(4)  156.8(2) /172.2(2)  176.9(2) /172.7(2)  –163.3(2)  20.9 5.036(3) 79.7  
PHS –13.3(5)/–13.6(5) 167.1(3) /167.0(3)  –174.2(3) /–174.8(3)  –143.7(2) 40.5  5.019(4)  78.9  
PTT –135.5(4) /–135.5(4)  –173.4(2) /–173.4(2)  66.6(3) /66.6(3)  –52.8(3)  7.2  3.977(3) 74.0  
PBT 20.7(2) / –13.8(2)  55.4(2) / 170.8(1)  172.8(1) / –176.7(1)  126.2(3)  6.6  5.017(2)  14.4  
PN –10.1(2) / –137.0(2) 65.8(2) / 166.0(1)  163.8(1) / –165.3(1)  –2.3  6.8  4.961(2)  22.9  
a Dihedral angles (deg) describing the mutual orientations of rotatable bonds (see Figure 2). τ1a/τ1b  correspond to the atom 
sequence C3–C4–N9–C10 / C23–C24–N29–C30, τ2a/τ2b to C11–N14–C15–C16/C33–N34–C17–C16 and τ3a/τ3b to N14–
C15–C16–C17 / N34–C17–C16–C15.   
b Dihedral angle (deg) expressing the mutual tilting of the quinoline moieties through the C4A–C4–C24–C24A atom 
sequence. 
c Angle (deg) between the least square planes of the quinoline backbones. It describes whether they are planar or not. 
d Distance (Å) between the protonated piperazine N atoms. It describes how much the structure is compact or stretched. 
e Angle (deg) between the piperazine backbone least squares planes. 
 
Another useful descriptor of the overall folding is the distance between the piperazine N 
atoms, dNN, across the central hydrocarbon –(CH2)3– linker. To the sake of comparison, in crystalline 
pentane (CSD refcode: PENTAN01), where neighboring methylene groups are almost perfectly 
antiperiplanar, the two terminal –CH3 groups lie 5.072 Å apart. While in PPT, PHS, and PBT the 
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hydrocarbon linker is fully extended, H4PQ4+ ions assume a sort of bent conformation at least in PTT, 
where dNN ≈ 3.9 Å, and possibly in PN, with dNN ≈ 4.9 Å (Table 2). The angle between the piperazine 
ring mean planes (αPA), finally, can give an indication of the mutual orientation of the aliphatic N–H 
groups involved in hydrogen bonding (see Section S2 SI). When this descriptor is relatively small 
(<60°), N–H bonds are oriented in the same direction, with the dihedral angle defined by the atom 
sequence H14–N14···N34–H34 as low as –9(2)º (PBT) or –6(2)º (PN). On the contrary, αPA >60° 
implies that aliphatic N–H groups are mutually orthogonal to each other, the same dihedral being as 
large as 90(3)º (PPT), 96(2)º (PHS) and 92(4)º (PTT). It is easy to see that αPA correlates with τQ, i.e. 
molecules with an anti– (syn–) conformation also bear collinear (orthogonal) N–H groups. However, 
the main features of the hydrogen bond patterns, such as the ability of setting up strong CAHBs 
(Section 3.1), are qualitatively conserved independent on the piperaquine conformation.  
 
3.3 Solubility of PQ salts. Figure 3 shows the estimates for the solubilities (S) of the PQ salts 
as a function of T, referred to wavelengths of 349 nm in H2O and of 344 nm in acetic acid (Section 
2.3). These were selected according to the maxima found during the calibration procedure; the 
interested reader can find full details in Sections S6 and S7 SI. All the compounds show an 
exponential dependence on T. Solubilities in an acidic environment are slightly larger than in water, 
likely due to the different ionic strength of the resulting solution (Figure 3b and Tables S11–S12 SI). 
However, the difference is barely appreciable and in the subsequent thermodynamic analysis, the 
average S estimates were employed. Upon linearization (Figure S9 SI), the least–squares fittings 
based on the functional form log10S=m⋅T–q, S being the solubility and T the temperature, give 
identical m and q parameters in both solvents within the statistical tolerance of 1–3 estimated standard 
deviations (Table S13). The highest solubility is invariably associated to the bromide salt (PBT). At 
20 °C, the latter is ten times more soluble than PHS and almost two times more soluble than PPT. 
Moreover, S(PBT) increases faster than all the other compounds, and escalates by roughly 740 % on 
going from 20 ºC to 50 ºC (293 – 323 K). At T = 20 ºC, the solubilities of the other salts follow the 
sequence S(PHS) << S(PPT) < S(PTT), and this order is strictly conserved up to 50 ºC. The nitrate 
PN, on the contrary, behaves quite differently, as the corresponding curve has a slope comparable 
with that of PBT. As a consequence, PN bears at T = 20 ºC a solubility comparable with that of least 
soluble hydrogen sulfate, PHS; then, S(PN) quickly increases, until it crosses the curves of PPT (T > 
35 ºC, 308 K) and even PTT (T > 40 ºC, 313 K). Clearly, this process is slightly faster in AcOH 1 M. 
No other curve shows a similar behavior, which may be related to the fact that PN, at variance with 
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most of the other crystal structures here examined, does not bear disordered co–formers its lattice 
(see Section S2.7 SI and Section 4 below). 
 
Figure 3. Solubility curves of PQ salts (PPT: hydrogen phosphate, open triangles; PHS: hydrogen 
sulfate, circles; PTT: triflate, diamonds; PBT: bromide, full triangles; PN: nitrate, squares) as a 
function of T. Vertical bars correspond to 1 estimated standard deviations (e.s.d.’s); in most cases, 
they are smaller than the dimension of the corresponding experimental point. Full broken lines serve 
just as a guide for the eye. (a) Measurements in water. (b) Measurements in AcOH 1 M.  
 
3.4. Hydration. Solubility is usually related to the lattice energy, and thus to relevant non–
covalent interactions among the molecules in the crystalline state.56 Accordingly, it can be correlated, 
though not exclusively, to the melting point.57 However, solute–solvent interactions and entropic 
effects in solution58 are important as well, implying that no obvious rules exist that allow predicting 
the solubility of a given compound just from the sole knowledge of its crystal structure. The problem 
is further complicated in co–crystals and molecular salts, which contain more than one chemical 
specie.59 Even though it has been claimed that in multicomponent systems the lattice energy is 
determinant to rationalize the solubility,56 this is not the case for PQ salts. In agreement with previous 
studies,59 crystal cohesive energies, Ecoh (Table S14 SI), of the title compounds do not correlate with 
the measured solubilities (Figure S11 SI). To take into account explicitly solvent effects, Gibbs free 
hydration energies, ∆G*hyd, were estimated by quantum simulations in a polarizable continuum 
environment (Section 2.4). Thermodynamic state functions are derived from the corresponding 
electronic energies through the knowledge of the corresponding partition functions,60,61 assuming that 
each chemical specie behaves as a perfect gas. The superscript (*) here follows the Ben–Naim & 
Marcus62 terminology and implies the transfer of molecules between two phases at a fixed centres of 
mass in each phase. We assessed the accuracy of the method on the same test cases suggested by 
Misin et al.63 (Table S15 SI), finding that it was fully comparable to that achieved by other recipes, 
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even though our predictions for the hydration energies of the anions are underestimated to a certain 
extent (Table 3).  
 
Table 3. Hydration free energies (kJ·mol–1) of ions contained in PPT, PHS, PTT, PBT and PN 
piperaquine salts.  
 
Salt Ion NA/NPQa ∆G*hyd, expt.b ∆G*hyd, calc. ∆Ghyd,tot calc.c 
PPT 
H4PQ4+ 1 – –2110.3 –2110.3 
H2PO4– 4 –465 –314 –1256 
PHS 
H4PQ4+ 1 – –2110.3 –2110.3 
HSO4– 4 – –291 –2199 
SO42– 1d –1080 –1035 
PTT 
H4PQ4+ 1 – –2125.0 –2125.0 
CF3SO3– 4 – –232 –928 
PBT 
H4PQ4+ 1 – –2117.8 –2117.8 
Br– 5 –315 –226 –1130 
PN 
H4PQ4+ 1 – –2107.6 –2107.6 
NO3– 4 –300 –276 –1104 
a Ratio between the number of ions and the number of piperaquine molecules in the asymmetric unit 
b Experimental data, when available, where taken from ref. 64.  
c Total ∆G*hyd estimates, from the sum of all the contributions of ions with the same charge in the asymmetric unit. 
d The contribution of a single sulfate ion must be taken into account here, as the optimization of disordered hydrogen 
atoms predict a proton transfer between a HSO4– ion to a neutral water molecule (Section S3 SI).  
  
Table 3 reports the results for H4PQ4+ species and their anions in the various salts. As expected, 
the hydration free energies of the cations are very similar to each other. Differences not exceeding 18 
kJ·mol–1 reflect the conformational differences of the molecular ions in the various crystal structures 
(Section 3.2), with a standard deviation of ≈ 0.3 % with respect to the mean ∆G*hyd estimate. In any 
case, these differences are likely too small to account for the significant changes in solubility across 
the series of salts here examined (Section 3.3), which should be thus ascribed to the respective 
counterions. We note that, interestingly, the sulfate salt, whose anion sets up the most favourable 
interaction with water, is also the one with the lowest solubility.    
 
3.5. Thermodynamic cycle of solvation. From a thermodynamic viewpoint, the solvation reaction can 
be partitioned into a sublimation process, where the individual components of the crystal are brought 
into the gas phase at infinite distance, followed by hydration, upon which each ion is surrounded by 
interacting water molecules (Scheme 2). 
17 
 
 
Scheme 2.  
 
Altogether, sublimation, hydration and solvation form a closed thermodynamic cycle, 
meaning that the following equality holds true:  
∆
∗ = ∆	

∗ + ∆
∗      (2) 
Here, ∆G*hyd and ∆G*sub refer to hydration and sublimation energies. Moreover, assuming as unitary 
any activity coefficient, it has been shown58 that the Gibbs free energies of solvation are related to 
the experimental solubilities, S:  
∆
∗ =–RTln ∙      (3) 
Vm (the crystalline molar volume) being equal to: 
 = / ∙ ′     (4) 
NA is the Avogadro’s constant, Vcell the real cell volume, and Z and Z’ the number of asymmetric units 
in the unit cell, and the number of molecules in the asymmetric unit. Thus, Vm just represents the 
average volume per molecule in the crystal. Putting together (2) and (3), ∆G*sub can be computed 
directly from the experimental estimates of Sexp, once that a reasonable estimate of ∆G*hyd is known 
(Table 3). This method has been recently applied with success to first-principles prediction of aqueous 
solubilities of small organic molecules.56,65 In the present case, results for transformations taking 
place at T = 25 °C are shown in Table S16 SI. It turns out that the free energy of solvation is invariably 
small and positive, as it can be expected from the low solubilities of PQ salts (Section 3.3). Moreover, 
the free energies of sublimation correlate well with the corresponding lattice energies (Figure S12 
SI), i.e. the most negative Ecoh’s correspond to the highest sublimation free energies, and vice versa. 
This guarantees that the present predictions of thermodynamic quantities, though clearly approximate, 
are accurate enough to provide reliable results on relative grounds. 
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Table 4. Comparison of relevant outcomes of quantum simulations, measured solubilities and 
thermodynamic state functions for the title compounds.  
 
Substance S / mol·L–1 a ∆Sºsolv / kJ·mol–1·K–1 ∆Gºsub b/ kJ·mol–1 η(anions) /eV c Cpack
d 
PPT 0.0104  2.02 3543.8 3.20 70.6 
PHS 0.0017 2.09 5326.8 2.91 75.8 
PTT 0.0134  0.51 3162.3 2.96 67.3 
PBT 0.0209 2.04 3756.4 2.02 70.4 
PN 0.0045 1.11 3263.4 3.55 70.5 
a Average solubility in water and AcOH 1 M at T = 25 ºC (298 K). See also Tables S11–S12 SI.   
b Refer to Section S8.2 SI to see how ∆Gºsub are estimated from ∆G*sub.  
c Chemical hardness (in eV), defined as the average energy of the frontier orbitals according to η = (εLUMO–εHOMO)/2, 
under the assumption that the Koopmans’ theorem is valid. Following Pearson,66 η’s of anions at their optimized 
geometries were estimated from the corresponding neutral radicals.  
d Packing coefficient. It is defined as the ratio between the total volume occupied by molecules, in turn computed as the 
usual superposition of van der Waals hard spheres, and the total cell volume. Cpack represents the percent amount of space 
that is actually occupied within the crystal structure.  
 
The standard entropy of solvation, ∆Sºsolv, can be also estimated from the corresponding 
sublimation entropy, ∆Sºsub, if the equality ∆Sºsolv ≈ ∆Sºsub holds true. Such a hypothesis implies that 
the difference of entropy between the gas phase and the solution is small, or, equivalently, that the 
entropy changes associated to both (crystal → gas) and (crystal → solution) processes should bear 
similar magnitudes. This condition is certainly verified for ideal dilute solutions, i.e. for example in 
vivo, where the drug concentration ranges from nM (in the cytoplasm) up to µM (in the digestive 
vacuole).20 As for the present measurements (Tables S11 and S12 SI), where concentrations are of 
the mM order, the assumption of ideal behaviour can be still probably accepted with a reasonable 
level of confidence. A full description of the procedure exploited to estimate ∆Sºsub (and thus ∆Sºsolv), 
based on the recipe suggested by Palmer and co–workers,58 can be found in Section S8.2 SI. Table 4 
summarizes the most important outcomes of statistical thermodynamic and quantum simulations, 
relating them to the solubility of PQ salts in standard ambient conditions (T = 298 K, p = 1 bar), as 
they are usually taken as suitable thermodynamic reference. 
The solvation entropies of PHS, PPT and PBT have the same magnitude (Table 4). However, 
their solubilities are very different. Moreover, PTT is characterized by a ∆Sºsolv four times smaller 
than PHS and PPT, though it is more soluble than both are. This means that the entropy balance, by 
itself, poorly correlates with solubility. In the next Section, the trends in solubility are analysed from 
a more general perspective, taking also into account the Pearson’s estimates for anionic chemical 
hardnesses (see Table 4). 
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4. Discussion  
With the only exception of the PHS salt, there is a good linear correlation between the anion 
hardness (η) and the solubility of the title compounds in standard ambient conditions (Figure 4). In 
general, the lower the hardness of the counter–anion, the higher the solubility of the salt. This can be 
rationalized in the framework of the Hard and Soft Acids and Bases (HSAB) theory:67 due to their 
very large positive charge, H4PQ4+ species are expected to be hard acids, and tend to bound more 
tightly hard bases.  
 
Figure 4. Linear correlation between the chemical hardness of the anions (η, eV) vs. the average 
solubility (S, mol·L–1) of PQ salts at T = 25 ºC (298 K). Tabular entries can be found in Table 4. The 
curve has equation S = –0.010(1) η + 0.042(4), with R2 = 0.960. Error bars correspond to 1 estimated 
standard deviation (e.s.d.), as derived from the least squares fitting. The red dot at the bottom 
corresponds to the hydrogen sulfate structure and it has been not included into the fitting.  
 
The salt with the highest solubility, PQ bromide (PBT), contains indeed the softest anion (η 
= 2.02 eV, Table 4). Accordingly, the next ranking salt, triflate (PTT), has a higher η (2.96 eV). More 
interesting is the fact that, despite the sulfate salt PHS bears a comparable hardness (2.91 eV), is the 
least soluble on absolute grounds (Table 4). This is likely due to the intrinsically lower cohesion of 
the triflate crystal structure: PTT has the lowest packing coefficient and, accordingly, the lowest 
sublimation energy. Indeed, CF3SO3– is the largest anion in the whole set of structures here 
considered, and is definitely non-spherical. Thus, when paired with piperaquine, it is less able to 
occupy efficiently the available space. This complies well with the fact that, in PTT, H4PQ4+ species 
prefer to assume a ‘bent’ conformation, more compact and symmetrical, rather than the most common 
‘stretched’ one (Section 3.2). It is worth noting that PTT is also the only salt where two hydrogen 
bonds per PQ molecule involve neutral co–crystallized water molecules rather than charged anions 
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(Section 3.1). In contrast, in the bromide PBT, the higher solubility complies with a synergy of 
electronic (softness of Br–) and thermodynamic factors: the total hydration Gibbs free energy of Br– 
ions is ≈ 100 kJ·mol–1 more negative than that of the triflate ones (Table 3, Section 3.4), reflecting 
the higher molar amount of anions in the unit cell of PBT (Table 1 and Section S2.6 SI). Moreover, 
the Br– ion has one of the highest entropic contributions to the solvation energy (Table 4), even though 
the latter accounts for less than 20 % of the overall ∆G*solv (Table S16 SI). 
At the opposite extreme, PHS is the least soluble salt. Albeit being associated to an 
intermediate anion hardness (2.91 eV), PHS has the greatest sublimation free energy and the highest 
packing efficiency (Table 4). The very low solubility of this compound can be thus ascribed to a very 
high lattice stability. This latter, as in chloroquine6 and organic salts in general,49,68 is due to more 
favourable electrostatic interactions. A survey of Mulliken charges on oxygen and hydrogen atoms 
in organic anions (Table S17 SI), shows that HSO4– and SO42– moieties bear the highest negative 
charge on their external O and OH groups (–2.51 and –3.42 e) with respect to all the other species 
here considered (H2PO4–: –2.49 e; CF3SO3–: –2.36 e; NO3–: –1.68 e). This implies that stronger 
electrostatic interactions are set up in PHS, which implies that, on average, different molecules are 
kept very close to each other in the crystal, as it is evident from the occurrence of a lot of short H···H 
contacts (Section 3.1). As expected, a stronger network of non–covalent interactions reflects into 
more negative cohesive energy (Table S14 SI) and larger ∆G*sub (Table 4).  
The nitrate compound (PN) contains the hardest anion (η = 3.55 eV, Table 4), meaning that 
NO3– is expected to bear a greater affinity for protonated PQ than all the other anions here considered. 
Accordingly, the solubility of PN is very low at T = 25 ºC (298 K, Table 4). However, it also rapidly 
increases with T, becoming even higher than those of PPT and PTT for T > 40 ºC (313 K, Section 
3.3, Figure 3). It should be remarked that PN is the only compound that does not contain co–
crystallized water (Table 1) and, together with the most soluble PBT salt, it does not bear disordered 
groups (Sections 3.1 and S2.6 SI). On the contrary, PPT, PHS and PTT salts are all already partially 
disordered. Thus, their entropy gain upon solubilization is necessarily lower than expected, as our 
model for ∆Sºsolv completely neglects disorder effects. Disorder provides thus a rationale for the 
observed fast increment of solubilities of PBT and PN with T (Figure 3): the higher the temperature, 
the more favourable will be the entropy gain with respect to all the other structures upon 
solubilization.  
The hydrogen phosphate salt (PPT) is associated to a more efficient packing and a higher 
sublimation free energy than PN (Table 4). Nevertheless, it is almost 3 times more soluble than PQ 
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nitrate at T = 25 ° C, likely as H2PO4– anions have the most favourable hydration Gibbs free energy 
after the bromide ones (Table 3). This is easily explainable: at variance with NO3–, H2PO4– is 
amphiprotic, as it bears both acidic –OH functions (HB donors) and P=O free groups (HB acceptors). 
At the same time, however, PPT is also less soluble than the triflate PTT, according to the lower 
packing efficiency of the latter (see above).  
 
5. Conclusions 
In this work, five novel salts of piperaquine (PQ), a 4-aminoquinoline antiplasmodial 
employed in artemisinin12–combination therapies,1,13,14 were synthesized and thoroughly 
characterized by crystallographic, spectroscopic and computational methods. The study was 
motivated by the need of more effective formulations of known antimalarial drugs, and the main aim 
was to understand how and why the measured solubility of PQ compounds depends on chemical, 
crystallographic and electronic degrees of freedom.  
From a crystallographic viewpoint, solubility is related to structural and energetic properties 
of the lattice structure and crystal packing, but relevant solute–solvent interactions are known to be 
crucial factors as well. Accordingly, we found that the solubility of PQ cannot be related to just one 
specific structural or energetic aspect. Rather, it stems from the cooperative effects of several actors, 
even though the chemical hardness of the anions (η) seems to play a central role. According to the 
predictions of the HSAB theory, softer anions are generally associated to highly soluble salts. Only 
the hydrogen sulfate salt is totally off–trend, due to its exceptionally high lattice stability. At the same 
time, fully ordered compounds (bromide, nitrate), which experience a larger entropy gain upon 
solubilization, have solubilities that increase faster as T is raised with respect to salts bearing some 
kind of disorder (hydrogen phosphate, hydrogen sulfate, triflate). Other factors being similar, packing 
efficiency and crystal field strength become important, as for example the triflate compound is highly 
soluble at standard ambient conditions due to a lower packing coefficient, coupled to a less favourable 
number of charge-assisted hydrogen bonds per PQ molecule. On the contrary, parameters such as the 
solid-state conformation of protonated PQ, the nature of different π⋅⋅⋅π stacking modes, or the number 
and type of hydrogen bonds in the crystal, have no direct effect on the observed solubilities.  
From the present results, it seems that a good strategy to increase the solubility of PQ salts be 
the coupling of the drug with soft anions, in the sense of the HSAB theory. Moreover, selecting 
crystalline phases with low intrinsic disorder, or not disordered at all, will likely result in formulations 
that are more soluble at higher temperature – which
22 
 
and storage of the active pharmaceutical ingredient. Studies of other crystalline piperaquine salts 
containing anions suitable for human administration will be carried out in the next future. Hopefully, 
they will pave the way toward more effective administration modes of the drug, increasing the current 
toolbox of strategies aimed at finely tuning its bioavailability.  
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Synopsis: The solubility of salts of the antiplasmodial piperaquine depends on the mutual chemical 
affinity between the drug and its counter ions. 
 
